Interaction of Cyclooxygenase-2 Variants and Smoking in Pancreatic Cancer: A Possible Role of Nucleophosmin

Gastroenterology

Volumn 136, Issue 5, 2009, Pages 1659-1668

  Zhao, Dan ^a   Xu, Dongkui ^a   Zhang, Xuemei ^a   Wang, Li ^b   Tan, Wen ^a   Guo, Yongli ^a   Yu, Dianke ^a   Li, Hui ^b   Zhao, Ping ^a   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; CYCLOOXYGENASE 2; NUCLEOPHOSMIN;

ADULT; AGED; ARTICLE; BINDING SITE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 65249112214     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.01.071     Document Type: Article

References (39)

1. Li D., Xie K., Wolff R., et al. Pancreatic cancer. Lancet 363 (2004) 1049-1057
2. Koliopanos A., Avgerinos C., Paraskeva C., et al. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 7 (2008) 345-356
3. Malfertheiner P., and Schutte K. Smoking-a trigger for chronic inflammation and cancer development in the pancreas. Am J Gastroenterol 101 (2006) 160-162
4. Lowenfels A.B., and Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2006) 197-209
5. Farrow B., Sugiyama Y., Chen A., et al. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 239 (2004) 763-769
6. Garcea G., Dennison A.R., Steward W.P., et al. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 5 (2005) 514-529
7. Klein A.P., Hruban R.H., Brune K.A., et al. Familial pancreatic cancer. Cancer J 7 (2001) 266-273
8. Lilley M., and Gilchrist D. The hereditary spectrum of pancreatic cancer: the Edmonton experience. Can J Gastroenterol 18 (2004) 17-21
9. Chappuis P.O., Ghadirian P., and Foulkes W.D. The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Invest 19 (2001) 65-75
10. Malats N. Gene-environment interactions in pancreatic cancer. Pancreatology 1 (2001) 472-476
11. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7916
12. Ulrich C.M., Bigler J., and Potter J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6 (2006) 130-140
13. Schlosser W., Schlosser S., Ramadani M., et al. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25 (2002) 26-30
14. Albazaz R., Verbeke C.S., Rahman S.H., et al. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology 5 (2005) 361-369
15. Maitra A., Ashfaq R., Gunn C.R., et al. Cyclooxygenase-2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118 (2002) 194-201
16. Juuti A., Louhimo J., Nordling S., et al. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 59 (2006) 382-386
17. Tucker O.N., Dannenberg A.J., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
18. Schuller H.M., Zhang L., Weddle D.L., et al. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128 (2002) 525-532
19. Hitt E. Aspirin may lower risk of pancreatic cancer. Lancet Oncol 3 (2002) 518
20. Ferrari V., Valcamonico F., Amoroso V., et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 57 (2006) 185-190
21. Dixon D.A. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res 37 (2003) 52-71
22. Nie M., Pang L., Inoue H., et al. Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1β in human airway smooth muscle cells: involvement of different promoter elements, transcription factors, and histone h4 acetylation. Mol Cell Biol 23 (2003) 9233-9244
23. Zhang X., Miao X., Tan W., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129 (2005) 565-576
24. Wang L., Miao X., Tan W., et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 3 (2005) 743-751
25. Barrett J.C., Fry B., Maller J., et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
26. Lake S.L., Lyon H., Tantisira K., et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55 (2003) 56-65
27. Papafili A., Hill M.R., Brull D.J., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22 (2002) 1631-1636
28. Grisendi S., Bernardi R., Rossi M., et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437 (2005) 147-153
29. Szczeklik W., Sanak M., and Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 114 (2004) 248-253
30. Sanak M., Szczeklik W., and Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 116 (2005) 221-223
31. Schuller H.M. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2 (2002) 455-463
32. Duell E.J., Holly E.A., Bracci P.M., et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 94 (2002) 297-306
33. Anto R.J., Mukhopadhyay A., Shishodia S., et al. Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκB(α): correlation with induction of cyclooxygenase-2. Carcinogenesis 23 (2002) 1511-1518
34. Grisendi S., Mecucci C., Falini B., et al. Nucleophosmin and cancer. Nat Rev Cancer 6 (2006) 493-505
35. Di Fiore P.P. Playing both sides: nucleophosmin between tumor suppressor and oncogenesis. J Cell Biol 182 (2008) 7-9
36. Sportoletti P., Grisendi S., Majid S.M., et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 111 (2008) 3859-3862
37. Moons L.M., Kuipers E.J., Rygiel A.M., et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 102 (2007) 2373-2379
38. Gao J., Ke Q., Ma H.X., et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A 70 (2007) 908-915
39. Tan W., Wu J., Zhang X., et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28 (2007) 1197-1201